Drug Search Results

Rolipram

Alternative Names: rolipram
Latest Update: 2024-07-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: PDE4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rolipram

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis

Phase 1: Huntington Disease|Depressive Disorder|Depressive Disorder, Major|Brain Diseases

Trial	Phase	Trial Status	Disease	Primary Completion Date
000824-M	P1	Terminated	Depressive Disorder	2023-02-08
06-M-0215	P1	Completed	Depressive Disorder, Major	2016-06-16
NCT01602900	P1	Completed	Huntington Disease	2012-04-12
06-M-0002	P1	Completed	Brain Diseases	2009-02-05

Recent News Events

Date	Type	Title
07/30/2024	News Article	New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer's Disease Progression, and Response to Therapeutics
04/29/2024	PubMed	Enantioselective synthesis of β-aryl-γ-lactam derivatives via Heck-Matsuda desymmetrization of N-protected 2,5-dihydro-1H-pyrroles.
04/23/2024	PubMed	A Comparative Study of the Antiemetic Effects of α2-Adrenergic Receptor Agonists Clonidine and Dexmedetomidine against Diverse Emetogens in the Least Shrew (Cryptotis parva) Model of Emesis.
04/17/2024	PubMed	Cyclic AMP signaling promotes regeneration of cochlear synapses after excitotoxic or noise trauma.
03/12/2024	News Article	MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
09/27/2023	News Article	MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
02/28/2019	News Article	Rare Disease Repurposing Datathon from Elsevier and The Pistoia Alliance Reveals New Candidates for Potential Treatment of Chronic Pancreatitis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions